GoodRx announced that it is working with Eli Lilly and Company to expand access to the newly FDA-approved oral GLP-1 medication, Foundayo (orforglipron). Eligible self-pay patients can access Foundayo through GoodRx at a starting price of $149 per month, in line with the lowest available discounted cash price at launch. GoodRx is also expanding access to Zepbound (tirzepatide) KwikPen, available to eligible self-pay patients starting at $299 per month at more than 70,000 pharmacies nationwide.
Together with the launch of Foundayo, these offerings expand access to both oral and injectable GLP-1 treatments for adults seeking prescribed obesity care outside traditional insurance pathways. GoodRx?s role in expanding access to Foundayo reflects a broader shift in how innovative therapies reach patients. For many medications, particularly GLP-1 treatments prescribed for weight loss, insurance coverage remains inconsistent or unavailable, prompting manufacturers to explore new direct-to-consumer access models.
GoodRx supports this shift by combining transparent discounted cash pricing, nationwide pharmacy access, and a trusted consumer platform that helps patients start treatment while maintaining continuity of care and the ability to fill prescriptions at their pharmacy of choice.
